Even less is known about how these reasons differ between those using GLP-1 RAs as anti-obesity medications (AOMs) versus those using them for antidiabetic management (ADMs), or how these patterns have changed over time as awareness, access, and prescribing practices have evolved
A systematic review exploring complex risk communication, undertaken to support NICE guidelines on sunlight exposure [22], found that only tailored messages (i.e
Brand T, Macha S, Mattheus M, Pinnetti S, Woerle HJ
It is FDA-approved for male pattern baldness and used off-label in some female cases
MiR-370 targets CPT1A reducing FAO
Key highlights US-synthesized